Charles Schwab’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Charles Schwab’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-366,666	Closed	-$109K	–	3700
2023 Q2	$109K	Sell	366,666 -235,559	-39%	-$71K	﹤0.01%	3348
2023 Q1	$260K	Sell	602,225 -6,588	-1%	-$5.06K	﹤0.01%	3117
2022 Q4	$718K	Buy	608,813 +130,162	+27%	+$212K	﹤0.01%	2891
2022 Q3	$1.11M	Buy	478,651 +154,031	+47%	+$403K	﹤0.01%	2758
2022 Q2	$718K	Buy	324,620 +20,933	+7%	+$145K	﹤0.01%	2921
2022 Q1	$2.92M	Buy	+303,687	New	+$2.72M	﹤0.01%	2512

Charles Schwab's GRNA Position: Q3 2023 in Review

Charles Schwab sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 366,666 shares — an estimated $109K sold.

Charles Schwab first reported a position in GRNA in Q1 2022 and held it in 6 quarters. The position peaked at $2.92M in Q1 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Charles Schwab reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Charles Schwab sold 366,666 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $109K.
Charles Schwab first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 6 quarters.
Charles Schwab's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $2.92M in Q1 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.